Development and manufacture of an improved replication-deficient simian adenoviral vector to prevent COVID-19

  • Funded by Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: MC_PC_20018

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $100,510.35
  • Funder

    Department of Health and Social Care / National Institute for Health and Care Research (DHSC-NIHR), UK Research and Innovation (UKRI)
  • Principle Investigator

    Pending
  • Research Location

    United Kingdom, Europe
  • Lead Research Institution

    Vaccitech Ltd
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The University of Oxford and Vaccitech jointly developed and then exclusively out-licensed a serogroup E chimpanzee adenoviral vector vaccine encoding the SARS-CoV-2 spike glycoprotein to AstraZeneca. This vaccine, ChAdOx1 nCoV-19, given as a single dose, has moved into Phase 2/3 studies in the UK, and in August 2020 begins Phase 3 studies in the US and Brazil. There are concerns that anti-vector immunity to the ChAdOx1 backbone may limit early boosting responses, or even boosts given on a yearly basis. Vaccitech has developed an alternative serogroup C chimeric gorilla adenoviral vector vaccine ("GAdVac"), which has been shown in completed murine studies to elicit higher antibody and T cell immune responses than the ChAdOx1 candidates. Vaccitech is now developing the full-length spike glycoprotein encoding GAdVac candidate and will use this as both a stand-alone vaccine and evaluate the use of this candidate as a prime and a boost for the ChAdOx1 platform. Efficacy studies in ferrets will be pursued with Public Health England at Porton Down. The pre-master virus seed will be produced in the SOP- controlled Early Development Laboratories at Vaccitech in Oxford, and then transferred to Advent (Rome, Italy) for GMP manufacture. Advent has successfully made three GMP released lots of ChAdOx1 vectors for Vaccitech. Scientific advice will be sought from MHRA, and a formal GLP toxicology study will be performed due to the novelty of this vector. Within 12 months, the CTA to begin a Phase 1 immunogenicity study will be complete.